Tag Archives: Novo Nordisk

Novo Nordisk Acquires Cardior Pharmaceuticals in Billion-Euro Deal, Pioneering RNA Therapies for Heart Diseases

(IN BRIEF) EQT Life Sciences proudly announces Novo Nordisk’s acquisition of Cardior Pharmaceuticals, valuing the biopharmaceutical company at up to EUR 1.025 billion. Based in Hannover, Germany, Cardior specializes in RNA-based therapeutics for cardiovascular diseases, focusing initially on heart failure. … Read the full press release

Patients as Partners® Europe Announces the Launch of 8th Annual Meeting with 2024 Keynotes and Topics

(IN BRIEF) The Conference Forum announced the launch of the 8th annual Patients as Partners® Europe meeting, scheduled for May 14-15, 2024, at Plaisterers’ Hall in London, England. This event brings together pharma R&D and patient advocacy to discuss patient … Read the full press release

Novo Nordisk Hosts Capital Markets Day to Share Progress on Strategic Aspirations 2025

(IN BRIEF) Novo Nordisk is conducting a Capital Markets Day (CMD) to provide updates on its Strategic Aspirations 2025. The event will focus on various aspects, including corporate strategy, sustainability, research and development pipeline, and financial performance. Highlights include discussions … Read the full press release

Novo Nordisk’s Semaglutide Shows Promise in Kidney Outcomes Trial FLOW

(IN BRIEF) Novo Nordisk has announced promising headline results from the kidney outcomes trial FLOW, which compared injectable semaglutide 1.0 mg with placebo as an adjunct to standard care for people with type 2 diabetes and chronic kidney disease (CKD). … Read the full press release

Novo Nordisk Announces Annual General Meeting Date and Proposals for Board Re-election

(IN BRIEF) Novo Nordisk A/S has announced the date for its Annual General Meeting, scheduled for Thursday, March 21, 2024, at 14:00 CET. The meeting will be held partially electronically, allowing shareholders to participate either in person at Bella Center … Read the full press release

Almirall Secures Global Rights for Promising Dermatological Treatment, NN-8828, Targeting IL-21

(IN BRIEF) Almirall S.A., a leading pharmaceutical company specializing in medical dermatology, has finalized an exclusive license agreement with Novo Nordisk for the development and commercialization of NN-8828, an IL-21 blocking monoclonal antibody. This innovative treatment holds potential for various … Read the full press release

Novo Nordisk Initiates Groundbreaking Collaborations for Innovative Obesity and MASH Treatments

(IN BRIEF) Novo Nordisk has announced separate research collaborations with Omega Therapeutics and Cellarity Inc. to explore innovative treatment approaches for obesity and MASH (Metabolic Associated Fatty Liver Disease). The collaboration with Omega aims to develop an epigenomic controller to … Read the full press release

Novo Nordisk Announces Landmark Investment to Expand Kalundborg Manufacturing Facilities for Chronic Disease Therapies

(IN BRIEF) Novo Nordisk has unveiled plans to invest more than 42 billion Danish kroner starting in 2023 to expand its existing manufacturing facilities in Kalundborg, Denmark. This significant investment coincides with the company’s 100th anniversary and underscores Novo Nordisk’s … Read the full press release

DHL Reports Growing Demand for Sustainable Transport Solutions; Collaborates with Novo Nordisk to Decarbonize Air Freight

(IN BRIEF) DHL Global Forwarding is experiencing a rising demand for sustainable transport solutions using fuels like Sustainable Aviation Fuels. More shippers are requesting emissions transparency and exploring sustainable options, even with extra costs. DHL’s GoGreen Plus service, which uses … Read the full press release

Novo Nordisk’s SELECT Trial Shows Semaglutide 2.4 mg Cuts Cardiovascular Risk in Overweight and Obese Adults

(IN BRIEF) Novo Nordisk, a global healthcare company, has reported the headline findings from the SELECT cardiovascular outcomes trial. This double-blinded study assessed the impact of subcutaneous once-weekly semaglutide 2.4 mg in comparison to placebo as an adjunct to standard … Read the full press release

Novo Nordisk’s Bid for BIOCORP Set at 35.00 Euros per Share, Totaling 154 Million Euros

(IN BRIEF) Novo Nordisk A/S is in exclusive negotiations to acquire a controlling stake in BIOCORP Production SA, a French company specializing in medical device design and manufacturing. The acquisition would be followed by a mandatory tender offer for all … Read the full press release

Vereinbarung zur Herstellung von nachhaltigem E-Methanol, unterzeichnet von LEGO Group, Novo Nordisk und European Energy

(IN KÜRZE) Die LEGO Group und Novo Nordisk haben sich mit European Energy zusammengetan, um E-Methanol, eine kohlenstoffärmere Alternative zu herkömmlichem Kunststoff, für einen Teil ihrer Materialproduktion zu verwenden. European Energy wird E-Methanol aus erneuerbarer Energie und biogenem CO2 produzieren, … Read the full press release

Sustainable e-methanol production agreement signed by LEGO Group, Novo Nordisk, and European Energy

(IN BRIEF) The LEGO Group and Novo Nordisk have partnered with European Energy to use e-methanol, a lower-carbon alternative to conventional plastic, for some of their material production. European Energy will produce e-methanol from renewable energy and biogenic CO2, and … Read the full press release

Novo Nordisk et Aspect Biosystems collaborent pour créer des traitements modificateurs de la maladie pour le diabète et l’obésité

(ACTUALITÉ EN BREF) Novo Nordisk a annoncé une collaboration avec Aspect Biosystems pour développer des thérapies tissulaires bio-imprimées pour le traitement du diabète et de l’obésité. La collaboration tirera parti de la technologie de bioimpression d’Aspect et de l’expertise de … Read the full press release

Novo Nordisk and Aspect Biosystems collaborate to create disease-modifying treatments for diabetes and obesity

(IN BRIEF) Novo Nordisk has announced a collaboration with Aspect Biosystems to develop bioprinted tissue therapeutics for diabetes and obesity treatment. The collaboration will leverage Aspect’s bioprinting technology and Novo Nordisk’s expertise in stem cell differentiation and cell therapy development … Read the full press release

Novo Nordisk renforce son équipe de direction avec de nouvelles nominations

(ACTUALITÉ EN BREF) Novo Nordisk a annoncé des changements dans son équipe de direction. Monique Carter, l’actuelle vice-présidente exécutive de Global People & Organisation, quitte l’entreprise pour poursuivre une opportunité externe et sera remplacé par Tania Sabroe, qui a été … Read the full press release

Novo Nordisk strengthens executive team with new appointments

(IN BRIEF) Novo Nordisk has announced changes to its executive management team. Monique Carter, the current EVP of Global People & Organisation, is leaving the company to pursue an external opportunity and will be succeeded by Tania Sabroe, who has … Read the full press release

Danish Novo Nordisk to use millions of liters of sustainable aviation fuel to replace fossil fuel for all Kuehne+Nagel air freight shipments in 2022

12 million litres of SAF (sustainable aviation fuel) to minimise environmental impact of Novo Nordisk air freight globally Sustainable fuel offering to support customers’ pledge for carbon-neutral shipping Advocating for more sustainable fuel production and use (PRESS RELEASE) SCHINDELLEGI, 20-Oct-2022 … Read the full press release

Danish Novo Nordisk utilizará millones de litros de combustible de aviación sostenible para reemplazar el combustible fósil para todos los envíos de carga aérea de Kuehne+Nagel en 2022

12 millones de litros de SAF (combustible de aviación sostenible) para minimizar el impacto ambiental de la carga aérea de Novo Nordisk a nivel mundial Oferta de combustible sostenible para respaldar el compromiso de los clientes de envíos sin emisiones … Read the full press release

Liz Hewitt appointed Independent Non-Executive Director at Glencore plc

(PRESS RELEASE) BAAR, 18-Jul-2022 — /EuropaWire/ — Glencore (LON: GLEN), an Anglo-Swiss multinational commodity trading and mining company, has announced that Liz Hewitt has been appointed as an Independent Non-Executive Director at the company with effect as of 18 July … Read the full press release

Liz Hewitt nommée administrateur non exécutif indépendant de Glencore plc

(COMMUNIQUÉ DE PRESSE) BAAR, 18-Jul-2022 — /EuropaWire/ — Glencore (LON : GLEN), une multinationale anglo-suisse spécialisée dans le commerce et l’exploitation de matières premières société, a annoncé que Liz Hewitt a été nommée administratrice indépendante non exécutive de la société avec … Read the full press release

The SEB Nordic Equity fund named best fund in the Nordic region by Fondmarknaden.se, Sweden’s largest fund trading venue

(PRESS RELEASE) STOCKHOLM, 1-Feb-2022 — /EuropaWire/ — Skandinaviska Enskilda Banken AB (STO: SEB-A) (SEB), a Swedish financial group leader on the Nordic market, has announced that its SEB Nordic Equity fund has become the Nordic Fund of the Year according … Read the full press release

Der SEB Nordic Equity-Fonds wurde von Fondmarknaden.se, Schwedens größtem Handelsplatz für Fonds, zum besten Fonds in der nordischen Region gekürt

(PRESSEMITTEILUNG) STOCKHOLM, 1-Feb-2022 — /EuropaWire/ — Skandinaviska Enskilda Banken AB (STO: SEB-A) (SEB), ein schwedisches Finanzunternehmen Gruppenführer auf dem nordischen Markt, hat bekannt gegeben, dass sein SEB Nordic Equity-Fonds laut Fondmarknaden.se, Schwedens größtem Handelsplatz für Fonds, zum Nordic Fund of … Read the full press release